Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1

O’Hagan, Derek T.; Ugozzoli, Mildred; Barackman, J. D.; Singh, Manmohan; Kazzaz, Jina; Higgins, Keith; Vancott, T.C; Ott, Gary

doi:10.1016/s0264-410x(99)00522-8

Cited by 42 publications

(13 citation statements)

References 34 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Its superiority was further enhanced when delivered with microspheres leading to both CTL activity as well as humoral response across the species. Similar results were observed in baboons with PLG/ p24 in MF59 as compared with MF59 alone plus p24 (79).…”

Section: Mf59supporting

confidence: 84%

New age adjuvants and delivery systems for subunit vaccines

Koduri

Manocha

Sabhnani

et al. 2000

Indian J Clin Biochem

View full text Add to dashboard Cite

The dramatic advancements in the field of vaccinology has led to the formulation of chemically well defined vaccines composed of synthetic peptides and recombinant proteins derived from the immunologically dominant regions of the pathogens. Though these subunit vaccines are safer compared to the traditional vaccines they are known to be poorly immunogenic. This necessitates the use of adjuvants to enhance the immunogenicity of these vaccine formulations. The most common adjuvant for human use is alum. Research in the past has focused on the development of systemic immunity using conventional immunization protocols. In the present era, the emphasis is on the development and formulation of alternative adjuvants and delivery systems in generating systemic as well as mucosal immunity. This review mainly focuses on a variety of adjuvants (particulate as well as non-particulate) used with protective antigens of HIV, malaria, plague, leprosy using modified delivery vehicles. The experience of our laboratory and other researchers in this field clearly proves that these new age adjuvants and delivery systems undoubtedly generate enhanced immune response -both humoral and cell mediated. The choice of antigens, the nature of adjuvant used and the mode of delivery employed have a profound effect on the type of immune response generated. Besides the quantity, the quality of the antibodies generated also play a vital role in protection against these diseases. Some of the adjuvants and delivery systems used promoted high titre and affinity antibodies, which were shown to be cytophilic in nature, an important criteria in providing protection to the host. Thus the studies on these adjuvants/ delivery systems with respect to various infectious diseases indicate their active role in efficient modulation of immune response along with safety and permissiblity.

show abstract

Section: Mf59supporting

confidence: 84%

New age adjuvants and delivery systems for subunit vaccines

Koduri

Manocha

Sabhnani

et al. 2000

Indian J Clin Biochem

View full text Add to dashboard Cite

show abstract

“…Liposomes have been shown to enhance the uptake of CpG ODN (16-mer) by immune cells in spleen and lymph nodes [440] and DC maturation by these adjuvants [438]. Other combinations include MPA/trehalose dicorynomycolate for a protein vaccine [445], chi-tosan/LTK63 (a nontoxic E. coli enterotoxin mutant) for DT-conjugated group C meningococcal polysaccharide antigen [446], chitosan/muramyl di-peptide (MDP) for Helicobacter pylori urease [230], PLG microparticles/ MF59 for recombinant protein antigens [447], PLGA particles/LPS for West Nile encephalitis [291], proteosome/LPS for influenza virus [448], QS-21 combinations with a variety of adjuvants for KLH-conjugated peptide vaccine [237], and FML (a glycoprotein complex) combinations with a variety of adjuvants for visceral leishmaniasis (VL) [449]. More complex adjuvant systems (3 adjuvant components) have also been tried.…”

Section: Adjuvant Combinationsmentioning

confidence: 99%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

“…Preparation of anionic microparticles was used effectively for delivery of adsorbed proteins and resulted in the induction of potent CTL and antibody responses to the HIV-1 p55 gag protein in mice [53]. In another HIV-1 vaccine study, a better immune response was obtained by formulating the antigen p24 into PLG microparticles and MF59 emulsion than with MF59 plus p24 alone, hence demonstrating the enhancing adjuvant capacity of microparticle formulation [54].…”

Section: Delivery Systemsmentioning

confidence: 99%

Bacterial ghosts as adjuvant particles

Riedmann

Kyd

Cripps

et al. 2007

Expert Review of Vaccines

View full text Add to dashboard Cite

The development of more advanced and effective vaccines is of great interest in modern medicine. These new-generation vaccines, based on recombinant proteins or DNA, are often less reactogenic and immunogenic than traditional vaccines. Thus, there is an urgent need for the development of new and improved adjuvants. Besides many other immunostimulatory components, the bacterial ghost (BG) system is currently under investigation as a potent vaccine delivery system with intrinsic adjuvant properties. BGs are nonliving cell envelope preparations from Gram-negative cells, devoid of cytoplasmic contents, while their cellular morphology and native surface antigenic structures remain preserved. Owing to the particulate nature of BGs and the fact that they contain many well known immune-stimulating compounds, BGs have the potential to enhance immune responses against ghost-delivered target antigens.

show abstract

Microparticles in MF59, a potent adjuvant combination for a recombinant protein vaccine against HIV-1

Cited by 42 publications

References 34 publications

New age adjuvants and delivery systems for subunit vaccines

New age adjuvants and delivery systems for subunit vaccines

Selection of Adjuvants for Enhanced Vaccine Potency

Bacterial ghosts as adjuvant particles

Contact Info

Product

Resources

About